Real-life data on the efficacy and safety of tezacaftor/ivacaftor in people living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation”

Activity: Talk or presentationTalk or presentation at a conference

Period2022
Event title45th European cystic fibrosis conference, Rotterdam
Event typeConference